Fluoptics is a young and innovative company in the field of fluorescence imaging for both clinical and preclinical applications. In clinics, Fluoptics develops solutions to optically guide cancer surgery. This approach is based on an intra-operative near infra-red fluorescence detector and fluorescent probes which specifically target tumors. This technology, extensively tested on animals, drastically improves cancer surgery in providing surgeons with an acute delineation of cancerous nodules during the surgery. Fluoptics develops and markets the Fluobeam, a unique fluorescence imaging system with an open design and an excellent sensitivity in the near infra-red spectrum. The company also proposes near infra-red molecular probes AngioStampTM for tumors and angiogenesis, and SentiDyeTM for vascular networks and lymphatic drainage. The instrument, as well as the probes, helps in understanding disease mechanisms and in developing new therapies.